The Patent Finder

Regenacy Pharmaceuticals, LLC

Also on record
Records under this name other than the patents Regenacy Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.

Showing 1 to 10 of 10 · Back to Regenacy Pharmaceuticals, LLC

PatentTitleStatus Expires Confidence
US 10,040,769Hdac Inhibitors for the Treatment of Diabetic Peripheral Neuropathy
Formerly held
Lapsed on the fee record
Ended Aug 7, 2026 · High confidence
Lapsed on the fee recordEnded Aug 7, 2026High confidence
US 9,957,259Selective HDAC1 and HDAC2 inhibitors
Lapsed on the fee record
Ended May 1, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 1, 2026From the USPTO record
US 9,790,180Piperidine Derivatives as HDAC1/2 Inhibitors
Lapsed on the fee record
Ended Oct 17, 2025 · High confidence
Lapsed on the fee recordEnded Oct 17, 2025High confidence
US 9,765,066Selective HDAC1 and HDAC2 inhibitors
Lapsed on the fee record
Ended Sep 19, 2025 · From the USPTO record
Lapsed on the fee recordEnded Sep 19, 2025From the USPTO record
US 11,013,740Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy
Lapsed on the fee record
Ended May 25, 2025 · High confidence
Lapsed on the fee recordEnded May 25, 2025High confidence
US 10,968,180Piperidine Derivatives as HDAC1/2 Inhibitors
Lapsed on the fee record
Ended Apr 6, 2025 · High confidence
Lapsed on the fee recordEnded Apr 6, 2025High confidence
US 9,562,013Selective HDAC3 inhibitors
Lapsed on the fee record
Ended Feb 7, 2025 · From the USPTO record
Lapsed on the fee recordEnded Feb 7, 2025From the USPTO record
US 10,858,323Hdac Inhibitors for the Treatment of Diabetic Peripheral Neuropathy
Lapsed on the fee record
Ended Dec 8, 2024 · High confidence
Lapsed on the fee recordEnded Dec 8, 2024High confidence
US 10,774,056Substituted piperazines as selective HDAC1,2 inhibitors
Lapsed on the fee record
Ended Sep 15, 2024 · From the USPTO record
Lapsed on the fee recordEnded Sep 15, 2024From the USPTO record
US 9,421,212Selective HDAC1 and HDAC2 inhibitors
Lapsed on the fee record
Ended Aug 23, 2024 · From the USPTO record
Lapsed on the fee recordEnded Aug 23, 2024From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited